Strong Annual Results Driven by Record-Setting Revenues for Fifth Quarter in a Row, Setting Stage for Another Record Year in 2026

LAS VEGAS, NV / ACCESS Newswire / April 2, 2026 / Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported preliminary unaudited results for year ended December 31, 2025. All comparisons are to the same year-ago period unless otherwise noted.

2025 Financial Highlights

• 2025 net revenue is expected to increase 45% to a record $4.5 million, with the increase due to the merger with Gummy USA, continued technological innovation, product line and distribution channel expansion, and strengthening direct-to-consumer and retail sales. Existing operations generated net revenue growth of approximately 25%.

• Direct-to-consumer product subscriptions increased 47% and Amazon "Subscribe & Save" customers increased 36% in 2025. Subscription customer growth continued to expand the company's recurring revenue stream and increase customer lifetime value while enhancing customer communications and retention.

2025 Operational Highlights

• At the beginning of the fourth quarter, completed the strategic merger with Florida-based Gummy USA^™, a leading developer and advanced manufacturer of precision-dosed nutraceutical gummies. The merger added Gummy USA's HACCP, GMP-certified and FDA-registered manufacturing facility expanded Healthy Extracts' vertical integration of R&D, outsourced manufacturing, marketing and distribution. Combined with Healthy Extracts' existing exclusive delivery systems (gel-packs and functional drinking straws), Gummy USA has unlocked a third specialized product development and marketing channel comprised of precision-dosed gummies for the nutraceutical and pharmaceutical markets.

• The Gummy USA Florida manufacturing facility and in-house R&D has begun to accelerate Healthy Extracts' overall product development and manufacturing process, enhance gross margins, and substantially strengthen the company's IP portfolio.

• Don Swanson, seasoned entrepreneur and manufacturing engineer and Gummy USA founder, was appointed CEO and chairman of Healthy Extracts. He further strengthened the management team as a recognized innovator in the fast-growing $13 billion global gummy supplement market. He invented and developed advanced, patent-pending white-label and private-label manufacturing solutions tailored for the health & wellness and pharma markets.

• Announced major 6 million nutraceutical gummy follow-on order from a woman's health nutraceutical leader. The gummies address a specialized need and were formulated under the guidance of the client's team of top-rated doctors, clinical professors and healthcare professionals, including board-certified internists, best-selling authors and leaders in family medicine.

• Launched STAT10, a revolutionary heart health formulation containing CoQ10, Berberine and Citrus Bergamot SuperFruit^™. The product expanded Healthy Extracts' addressable market beyond general heart health to supporting the unmet nutritional needs of 40 million existing statin users in the U.S. Clinically formulated to support nutrients inhibited by statins, STAT10 addresses the common side effects of muscle and joint pain, weakness and tiredness often associated with statins. STAT10 ingredients have been shown in clinical research to support heart health and the nutrients inhibited by statins.

• Launched 4Sleep, a natural, science-based healthy sleep formulation specially designed to support deeper, more restorative rest.

• Introduced the WHITNEY JOHNS^™ Gut Health Straw^™, the world's first fiber prebiotic and probiotic delivery straw. The innovative product was developed in partnership with fitness influencer and health advocate, Whitney Johns. Designed for maximum convenience and effectiveness, the product enables consumers to easily enjoy the gut health benefits of a naturally flavored, sugar-free prebiotic and probiotic blend by simply sipping a straw-no pills, powders or hassles. The product targets the fast-growing digestive health products market that is expected to more than double to $105 billion by 2033, according to Precedence Research.

• Expanded partnership with Gelteq Limited (NASDAQ: GELS), the clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and sports. Building upon the success of a co-developed product line of on-the-go gel-pack products, Healthy Extracts has become Gelteq's exclusive North American manufacturing, storage, shipping and fulfillment partner. The deeper collaboration is expected to reduce fulfillment costs and unlock higher margin sales opportunities.

• Maintained top three category ranking on Amazon.com, with the strong sales and customer acquisition performance due to the company's highly optimized sales and marketing strategies.

Management Commentary

"In the final quarter of 2025, we achieved record-setting net revenues for the fifth quarter in a row, with this driving another record year,' stated Healthy Extracts CEO and Gummy USA founder, Don Swanson.

"Our expected 45% year-over-year increase in net revenues, with 25% attributed to organic growth, reflects another M&A win along with strengthening performance across our direct-to-consumer and retail channels. Altogether, the year demonstrated how our well-tuned growth strategies continue to produce outsized results.

"During the year we also advanced the development of several new products and technologies across new categories, including products featuring our new fiber drinking straw and precision-dosed gummy manufacturing technologies. The commercial launch of these products benefits from the strategic cross promotion across our growing customer base and distribution channels.

"Our successful merger with Gummy USA last fall has been a strong catalyst for the transformation of our company, enabling us to execute on new growth strategies designed to expand our addressable market and strengthen our competitive position.

"This has involved intensifying our focus on our long-term strategic evolution toward leadership in Nutra Pharma technologies. Our operating performance in the first quarter is expected to remain consistent with the previous quarter and up dramatically year-over-year-all firmly in line with our growth plans and capital allocation priorities.

"Since the beginning of the year, we have been making great strides in our evolution into becoming a diversified platform addressing the high-growth, high-margin Nutra Pharma and Health & Beauty sectors.

"For the $636 billion health and beauty category, we enjoy tremendous opportunities to leverage our formulation capabilities, new manufacturing platform, and proprietary delivery technologies for new skin, hair and nail products, as well as broader health and wellness applications.

"Based upon our current commercial initiatives that include extensive new B2B customer engagement and product development, we see this category providing highly attractive opportunities to generate annualized revenue of more than $20 million by year end-or more than 4x above our current level. We believe this outlook is well supported by our current manufacturing facility and distribution capacity.

"We have also been making great strides in our clinical initiatives, acquiring FDA Pharma approval, clinical study readiness, and the development of regulatory property opportunities. We expect these efforts to support future product differentiation, scientific validation, and broad commercial adoption.

"Key to these efforts are our unique precision dose manufacturing capabilities and exclusive licensed delivery systems, We believe these provide valuable differentiation within the nutraceutical, Nutra Pharma and functional wellness markets.

"Through our advanced dosing technologies, proprietary gummy and gel-based delivery systems, and other exclusive oral delivery formats, we continue to position Healthy Extracts for success in health science, manufacturing innovation, and scalable commercialization.

"We believe we remain on track to further enhance shareholder value with our planned Nasdaq uplisting, with the Gummy USA merger and favorable capital structure helping us meet Nasdaq's listing requirements. We see the listing providing greater liquidity, institutional investor participation, more favorable M&A transactions, a higher valuation, and enable us to attract great new talent to our team. We see all of these positive elements coming into play as we work to make 2026 another stellar year for Healthy Extracts."

2026 Financial Outlook

Based on existing customer commitments and anticipated growth in order flow, the new Gummy USA unit is projected to generate additional substantial revenue growth in 2026, with its manufacturing facility potentially reaching its $20 million annual revenue production capacity during the year. This compares to $4.5 million in overall net revenue for the full year of 2025, for a potential increase of more than 344%.

New products across new categories and formats launched over the past year are expected to continue to drive growth with greater profitability (excluding non-cash-based expenses). New product launches are expected to benefit from the broad market channels the company has strategically invested in and developed over the last several years.

The company plans to drive future growth by reinvesting its cashflow and profits into new product development, sales and marketing, greater manufacturing capacity, potential acquisitions, and the further expansion of its distribution and sales channels.

Preliminary Results

The preliminary unaudited results presented in this press release are estimates only and are subject to revision until the company officially reports its audited 2025 results to be filed in Form 10-K with the SEC.

About Healthy Extracts "Live Life Young Again"

Healthy Extracts Inc. (OTCQB:HYEX) is a leader in nutraceutical innovations and precision dose gummy manufacturing. It develops, manufactures and markets proprietary, science-based supplements for brain, heart, and gut health. The platform enables clinically tested formulas and exclusive partnerships that deliver wellness solutions with measurable consumer and shareholder value.

The company's Gummy USA^™ subsidiary is a leading developer and manufacturer of precision-dosed nutraceutical and pharmaceutical-grade gummies. Its exclusive licensing proprietary patent-pending SureDose^™ technology delivers superior safety, efficacy and compliance for white and private label customers.

Healthy Extracts wholly owned subsidiaries, BergametNA^™ and Ultimate Brain Nutrients^™ (UBN), offer nutraceutical natural heart and brain health supplements. BergametNA products are the only heart health supplements distributed in North America containing Citrus Bergamot SuperFruit^™, the only superfruit with the highest known concentration of polyphenols and flavonoids.

Healthy Extracts has exclusive agreements for other innovative oral delivery systems that include Gelteq gel-packs and the Gut Health Straw, both of which provide superior bioavailability and ultimate consumer convenience.

To learn more, go to: healthyextractsinc.com, bergametna.com, tryubn.com or gummyusa.com.

Forward-Looking Statements and Safe Harbor Notice

All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on April 1, 2025, and future periodic reports filed with the U.S. Securities and Exchange Commission (SEC). All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only to the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.

Food & Drug Administration Disclosure

The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor's advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

Gummy USA ^™, BergametNA^™, Ultimate Brain Nutrients^™, UBN^™, Citrus Bergamot SuperFruit^™ and F4T^® are trademarks and registered trademarks of Healthy Extracts^™ Inc.

Company Contact

Duke Pitts, President & COO
Healthy Extracts Inc.
Tel (720) 463-1004
Email contact

Investor Contact

CMA Investor Relations
Tel (949) 432-7554
Email contact

SOURCE: HEALTHY EXTRACTS INC.